note_id,chart_date,category,text,subject_id
1,2018-03-12,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2018-03-12
PATIENT: HCC_Ideal_Candidate_for_TATE_Trial

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 123.25 ng/mL
- Total Bilirubin: 1.68 mg/dL
- Creatinine: 0.99 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7, Chronic Hepatitis B (Well-controlled). Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000000
2,2018-04-27,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2018-04-27
PATIENT: HCC_Ideal_Candidate_for_TATE_Trial

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000000
3,2018-06-13,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2018-06-13
PATIENT: HCC_Ideal_Candidate_for_TATE_Trial

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000000
4,2018-08-11,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2018-08-11
PATIENT: HCC_Ideal_Candidate_for_TATE_Trial

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000000
5,2018-09-19,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2018-09-19
PATIENT: HCC_Ideal_Candidate_for_TATE_Trial

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 137.46 ng/mL
- Total Bilirubin: 1.99 mg/dL
- Creatinine: 0.96 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7, Chronic Hepatitis B (Well-controlled). Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000000
6,2018-10-07,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2018-10-07
PATIENT: HCC_Ideal_Candidate_for_TATE_Trial

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 128.89 ng/mL
- Total Bilirubin: 2.26 mg/dL
- Creatinine: 0.83 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7, Chronic Hepatitis B (Well-controlled). Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000000
7,2018-11-06,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2018-11-06
PATIENT: HCC_Ideal_Candidate_for_TATE_Trial

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000000
8,2018-11-18,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2018-11-18
PATIENT: HCC_Ideal_Candidate_for_TATE_Trial

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 98.13 ng/mL
- Total Bilirubin: 1.67 mg/dL
- Creatinine: 0.75 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7, Chronic Hepatitis B (Well-controlled). Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000000
9,2018-12-04,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2018-12-04
PATIENT: HCC_Ideal_Candidate_for_TATE_Trial

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 112.76 ng/mL
- Total Bilirubin: 1.64 mg/dL
- Creatinine: 0.73 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7, Chronic Hepatitis B (Well-controlled). Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000000
10,2018-12-25,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2018-12-25
PATIENT: HCC_Ideal_Candidate_for_TATE_Trial

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000000
11,2019-01-06,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2019-01-06
PATIENT: HCC_Ideal_Candidate_for_TATE_Trial

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000000
12,2019-01-17,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2019-01-17
PATIENT: HCC_Ideal_Candidate_for_TATE_Trial

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 179.54 ng/mL
- Total Bilirubin: 1.5 mg/dL
- Creatinine: 0.89 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7, Chronic Hepatitis B (Well-controlled). Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000000
13,2019-02-03,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2019-02-03
PATIENT: HCC_Ideal_Candidate_for_TATE_Trial

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000000
14,2019-03-28,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2019-03-28
PATIENT: HCC_Ideal_Candidate_for_TATE_Trial

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000000
15,2019-04-23,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2019-04-23
PATIENT: HCC_Ideal_Candidate_for_TATE_Trial

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 123.21 ng/mL
- Total Bilirubin: 1.71 mg/dL
- Creatinine: 0.99 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7, Chronic Hepatitis B (Well-controlled). Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000000
16,2019-05-27,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2019-05-27
PATIENT: HCC_Ideal_Candidate_for_TATE_Trial

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 130.25 ng/mL
- Total Bilirubin: 1.1 mg/dL
- Creatinine: 1.02 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7, Chronic Hepatitis B (Well-controlled). Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000000
17,2019-06-17,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2019-06-17
PATIENT: HCC_Ideal_Candidate_for_TATE_Trial

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 170.59 ng/mL
- Total Bilirubin: 0.75 mg/dL
- Creatinine: 1.04 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7, Chronic Hepatitis B (Well-controlled). Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000000
18,2019-08-01,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2019-08-01
PATIENT: HCC_Ideal_Candidate_for_TATE_Trial

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 203.88 ng/mL
- Total Bilirubin: 0.64 mg/dL
- Creatinine: 0.96 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7, Chronic Hepatitis B (Well-controlled). Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000000
19,2019-08-19,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2019-08-19
PATIENT: HCC_Ideal_Candidate_for_TATE_Trial

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000000
20,2019-09-07,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2019-09-07
PATIENT: HCC_Ideal_Candidate_for_TATE_Trial

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 175.34 ng/mL
- Total Bilirubin: 0.24 mg/dL
- Creatinine: 1.08 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7, Chronic Hepatitis B (Well-controlled). Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000000
21,2019-09-22,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2019-09-22
PATIENT: HCC_Ideal_Candidate_for_TATE_Trial

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000000
22,2019-10-18,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2019-10-18
PATIENT: HCC_Ideal_Candidate_for_TATE_Trial

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000000
23,2019-11-25,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2019-11-25
PATIENT: HCC_Ideal_Candidate_for_TATE_Trial

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 127.94 ng/mL
- Total Bilirubin: 1.13 mg/dL
- Creatinine: 1.04 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7, Chronic Hepatitis B (Well-controlled). Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000000
24,2019-12-22,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2019-12-22
PATIENT: HCC_Ideal_Candidate_for_TATE_Trial

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 50.53 ng/mL
- Total Bilirubin: 1.06 mg/dL
- Creatinine: 0.93 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7, Chronic Hepatitis B (Well-controlled). Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000000
25,2020-01-02,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2020-01-02
PATIENT: HCC_Ideal_Candidate_for_TATE_Trial

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 70.96 ng/mL
- Total Bilirubin: 0.99 mg/dL
- Creatinine: 0.86 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7, Chronic Hepatitis B (Well-controlled). Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000000
26,2020-02-14,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2020-02-14
PATIENT: HCC_Ideal_Candidate_for_TATE_Trial

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 111.75 ng/mL
- Total Bilirubin: 0.85 mg/dL
- Creatinine: 0.65 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7, Chronic Hepatitis B (Well-controlled). Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000000
27,2020-02-14,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2020-02-14
PATIENT: HCC_Ideal_Candidate_for_TATE_Trial

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000000
28,2020-03-07,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2020-03-07
PATIENT: HCC_Ideal_Candidate_for_TATE_Trial

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000000
29,2020-03-23,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2020-03-23
PATIENT: HCC_Ideal_Candidate_for_TATE_Trial

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 93.63 ng/mL
- Total Bilirubin: 1.26 mg/dL
- Creatinine: 0.88 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7, Chronic Hepatitis B (Well-controlled). Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000000
30,2020-04-28,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2020-04-28
PATIENT: HCC_Ideal_Candidate_for_TATE_Trial

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000000
31,2020-06-18,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2020-06-18
PATIENT: HCC_Ideal_Candidate_for_TATE_Trial

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 89.61 ng/mL
- Total Bilirubin: 1.22 mg/dL
- Creatinine: 1.3 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7, Chronic Hepatitis B (Well-controlled). Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000000
32,2020-07-21,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2020-07-21
PATIENT: HCC_Ideal_Candidate_for_TATE_Trial

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 75.39 ng/mL
- Total Bilirubin: 0.82 mg/dL
- Creatinine: 1.34 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7, Chronic Hepatitis B (Well-controlled). Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000000
33,2020-08-28,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2020-08-28
PATIENT: HCC_Ideal_Candidate_for_TATE_Trial

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000000
34,2020-09-21,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2020-09-21
PATIENT: HCC_Ideal_Candidate_for_TATE_Trial

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 60.38 ng/mL
- Total Bilirubin: 0.99 mg/dL
- Creatinine: 1.39 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7, Chronic Hepatitis B (Well-controlled). Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000000
35,2020-10-07,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2020-10-07
PATIENT: HCC_Ideal_Candidate_for_TATE_Trial

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 78.0 ng/mL
- Total Bilirubin: 1.11 mg/dL
- Creatinine: 1.49 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7, Chronic Hepatitis B (Well-controlled). Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000000
36,2020-11-18,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2020-11-18
PATIENT: HCC_Ideal_Candidate_for_TATE_Trial

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000000
37,2020-12-21,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2020-12-21
PATIENT: HCC_Ideal_Candidate_for_TATE_Trial

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000000
38,2021-01-17,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2021-01-17
PATIENT: HCC_Ideal_Candidate_for_TATE_Trial

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 57.91 ng/mL
- Total Bilirubin: 0.52 mg/dL
- Creatinine: 1.57 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7, Chronic Hepatitis B (Well-controlled). Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000000
39,2021-05-16,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2021-05-16
PATIENT: HCC_Ideal_Candidate_for_TATE_Trial

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 23.32 ng/mL
- Total Bilirubin: 0.42 mg/dL
- Creatinine: 1.44 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7, Chronic Hepatitis B (Well-controlled). Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000000
40,2021-06-22,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2021-06-22
PATIENT: HCC_Ideal_Candidate_for_TATE_Trial

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 24.16 ng/mL
- Total Bilirubin: 0.77 mg/dL
- Creatinine: 1.51 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7, Chronic Hepatitis B (Well-controlled). Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000000
41,2021-07-14,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2021-07-14
PATIENT: HCC_Ideal_Candidate_for_TATE_Trial

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000000
42,2021-09-07,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2021-09-07
PATIENT: HCC_Ideal_Candidate_for_TATE_Trial

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000000
43,2021-09-20,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2021-09-20
PATIENT: HCC_Ideal_Candidate_for_TATE_Trial

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: -14.32 ng/mL
- Total Bilirubin: 1.83 mg/dL
- Creatinine: 1.37 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7, Chronic Hepatitis B (Well-controlled). Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000000
44,2021-10-10,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2021-10-10
PATIENT: HCC_Ideal_Candidate_for_TATE_Trial

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: -38.91 ng/mL
- Total Bilirubin: 2.03 mg/dL
- Creatinine: 1.3 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7, Chronic Hepatitis B (Well-controlled). Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000000
45,2021-10-19,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2021-10-19
PATIENT: HCC_Ideal_Candidate_for_TATE_Trial

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000000
46,2021-12-22,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2021-12-22
PATIENT: HCC_Ideal_Candidate_for_TATE_Trial

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: -96.62 ng/mL
- Total Bilirubin: 1.79 mg/dL
- Creatinine: 0.79 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7, Chronic Hepatitis B (Well-controlled). Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000000
47,2022-01-20,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2022-01-20
PATIENT: HCC_Ideal_Candidate_for_TATE_Trial

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: -17.71 ng/mL
- Total Bilirubin: 2.19 mg/dL
- Creatinine: 0.81 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7, Chronic Hepatitis B (Well-controlled). Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000000
48,2022-04-28,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2022-04-28
PATIENT: HCC_Ideal_Candidate_for_TATE_Trial

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: -49.26 ng/mL
- Total Bilirubin: 1.92 mg/dL
- Creatinine: 0.49 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7, Chronic Hepatitis B (Well-controlled). Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000000
49,2022-05-13,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2022-05-13
PATIENT: HCC_Ideal_Candidate_for_TATE_Trial

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: -28.31 ng/mL
- Total Bilirubin: 1.48 mg/dL
- Creatinine: 0.4 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7, Chronic Hepatitis B (Well-controlled). Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000000
50,2022-06-09,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2022-06-09
PATIENT: HCC_Ideal_Candidate_for_TATE_Trial

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000000
51,2022-08-14,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2022-08-14
PATIENT: HCC_Ideal_Candidate_for_TATE_Trial

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 62.2 ng/mL
- Total Bilirubin: 1.58 mg/dL
- Creatinine: 0.35 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7, Chronic Hepatitis B (Well-controlled). Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000000
52,2022-08-22,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2022-08-22
PATIENT: HCC_Ideal_Candidate_for_TATE_Trial

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000000
53,2022-09-12,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2022-09-12
PATIENT: HCC_Ideal_Candidate_for_TATE_Trial

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 63.82 ng/mL
- Total Bilirubin: 1.23 mg/dL
- Creatinine: 0.42 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7, Chronic Hepatitis B (Well-controlled). Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000000
54,2022-10-12,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2022-10-12
PATIENT: HCC_Ideal_Candidate_for_TATE_Trial

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 35.88 ng/mL
- Total Bilirubin: 1.15 mg/dL
- Creatinine: 0.53 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7, Chronic Hepatitis B (Well-controlled). Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000000
55,2022-10-25,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2022-10-25
PATIENT: HCC_Ideal_Candidate_for_TATE_Trial

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000000
56,2022-11-16,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2022-11-16
PATIENT: HCC_Ideal_Candidate_for_TATE_Trial

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 25.8 ng/mL
- Total Bilirubin: 1.21 mg/dL
- Creatinine: 0.56 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7, Chronic Hepatitis B (Well-controlled). Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000000
1,2018-02-04,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2018-02-04
PATIENT: HCC_Candidate_Excluded_by_Recent_GI_Bleed

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000001
2,2018-03-01,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2018-03-01
PATIENT: HCC_Candidate_Excluded_by_Recent_GI_Bleed

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000001
3,2018-03-17,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2018-03-17
PATIENT: HCC_Candidate_Excluded_by_Recent_GI_Bleed

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 90.17 ng/mL
- Total Bilirubin: 1.1 mg/dL
- Creatinine: 0.64 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7 with Esophageal Varices. Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000001
4,2018-05-05,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2018-05-05
PATIENT: HCC_Candidate_Excluded_by_Recent_GI_Bleed

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000001
5,2018-06-09,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2018-06-09
PATIENT: HCC_Candidate_Excluded_by_Recent_GI_Bleed

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 136.12 ng/mL
- Total Bilirubin: 1.16 mg/dL
- Creatinine: 0.3 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7 with Esophageal Varices. Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000001
6,2018-07-15,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2018-07-15
PATIENT: HCC_Candidate_Excluded_by_Recent_GI_Bleed

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 129.41 ng/mL
- Total Bilirubin: 1.11 mg/dL
- Creatinine: 0.31 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7 with Esophageal Varices. Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000001
7,2018-08-13,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2018-08-13
PATIENT: HCC_Candidate_Excluded_by_Recent_GI_Bleed

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 125.17 ng/mL
- Total Bilirubin: 1.37 mg/dL
- Creatinine: 0.35 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7 with Esophageal Varices. Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000001
8,2018-10-05,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2018-10-05
PATIENT: HCC_Candidate_Excluded_by_Recent_GI_Bleed

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 143.87 ng/mL
- Total Bilirubin: 1.81 mg/dL
- Creatinine: 0.44 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7 with Esophageal Varices. Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000001
9,2018-10-14,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2018-10-14
PATIENT: HCC_Candidate_Excluded_by_Recent_GI_Bleed

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000001
10,2018-12-16,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2018-12-16
PATIENT: HCC_Candidate_Excluded_by_Recent_GI_Bleed

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 123.1 ng/mL
- Total Bilirubin: 1.1 mg/dL
- Creatinine: 0.46 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7 with Esophageal Varices. Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000001
11,2019-01-12,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2019-01-12
PATIENT: HCC_Candidate_Excluded_by_Recent_GI_Bleed

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 109.38 ng/mL
- Total Bilirubin: 1.22 mg/dL
- Creatinine: 0.4 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7 with Esophageal Varices. Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000001
12,2019-01-15,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2019-01-15
PATIENT: HCC_Candidate_Excluded_by_Recent_GI_Bleed

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000001
13,2019-02-13,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2019-02-13
PATIENT: HCC_Candidate_Excluded_by_Recent_GI_Bleed

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000001
14,2019-02-20,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2019-02-20
PATIENT: HCC_Candidate_Excluded_by_Recent_GI_Bleed

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 98.82 ng/mL
- Total Bilirubin: 1.18 mg/dL
- Creatinine: 0.4 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7 with Esophageal Varices. Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000001
15,2019-03-04,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2019-03-04
PATIENT: HCC_Candidate_Excluded_by_Recent_GI_Bleed

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 98.88 ng/mL
- Total Bilirubin: 1.27 mg/dL
- Creatinine: 0.41 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7 with Esophageal Varices. Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000001
16,2019-05-27,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2019-05-27
PATIENT: HCC_Candidate_Excluded_by_Recent_GI_Bleed

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 130.89 ng/mL
- Total Bilirubin: 1.55 mg/dL
- Creatinine: 0.34 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7 with Esophageal Varices. Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000001
17,2019-06-01,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2019-06-01
PATIENT: HCC_Candidate_Excluded_by_Recent_GI_Bleed

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000001
18,2019-06-13,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2019-06-13
PATIENT: HCC_Candidate_Excluded_by_Recent_GI_Bleed

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 145.74 ng/mL
- Total Bilirubin: 1.26 mg/dL
- Creatinine: 0.31 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7 with Esophageal Varices. Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000001
19,2019-08-15,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2019-08-15
PATIENT: HCC_Candidate_Excluded_by_Recent_GI_Bleed

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000001
20,2019-08-25,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2019-08-25
PATIENT: HCC_Candidate_Excluded_by_Recent_GI_Bleed

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 151.81 ng/mL
- Total Bilirubin: 1.22 mg/dL
- Creatinine: 0.57 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7 with Esophageal Varices. Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000001
21,2019-09-13,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2019-09-13
PATIENT: HCC_Candidate_Excluded_by_Recent_GI_Bleed

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 160.68 ng/mL
- Total Bilirubin: 1.26 mg/dL
- Creatinine: 0.53 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7 with Esophageal Varices. Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000001
22,2019-10-04,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2019-10-04
PATIENT: HCC_Candidate_Excluded_by_Recent_GI_Bleed

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 189.46 ng/mL
- Total Bilirubin: 1.22 mg/dL
- Creatinine: 0.6 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7 with Esophageal Varices. Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000001
23,2019-10-11,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2019-10-11
PATIENT: HCC_Candidate_Excluded_by_Recent_GI_Bleed

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000001
24,2019-11-02,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2019-11-02
PATIENT: HCC_Candidate_Excluded_by_Recent_GI_Bleed

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000001
25,2020-01-04,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2020-01-04
PATIENT: HCC_Candidate_Excluded_by_Recent_GI_Bleed

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000001
26,2020-01-08,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2020-01-08
PATIENT: HCC_Candidate_Excluded_by_Recent_GI_Bleed

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 186.29 ng/mL
- Total Bilirubin: 1.6 mg/dL
- Creatinine: 0.51 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7 with Esophageal Varices. Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000001
27,2020-02-11,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2020-02-11
PATIENT: HCC_Candidate_Excluded_by_Recent_GI_Bleed

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 149.48 ng/mL
- Total Bilirubin: 1.26 mg/dL
- Creatinine: 0.5 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7 with Esophageal Varices. Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000001
28,2020-02-23,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2020-02-23
PATIENT: HCC_Candidate_Excluded_by_Recent_GI_Bleed

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000001
29,2020-03-01,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2020-03-01
PATIENT: HCC_Candidate_Excluded_by_Recent_GI_Bleed

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000001
30,2020-03-17,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2020-03-17
PATIENT: HCC_Candidate_Excluded_by_Recent_GI_Bleed

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 152.24 ng/mL
- Total Bilirubin: 1.32 mg/dL
- Creatinine: 0.4 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7 with Esophageal Varices. Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000001
31,2020-05-18,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2020-05-18
PATIENT: HCC_Candidate_Excluded_by_Recent_GI_Bleed

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000001
32,2020-07-23,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2020-07-23
PATIENT: HCC_Candidate_Excluded_by_Recent_GI_Bleed

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 197.35 ng/mL
- Total Bilirubin: 1.23 mg/dL
- Creatinine: 0.67 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7 with Esophageal Varices. Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000001
33,2020-09-28,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2020-09-28
PATIENT: HCC_Candidate_Excluded_by_Recent_GI_Bleed

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000001
34,2020-11-14,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2020-11-14
PATIENT: HCC_Candidate_Excluded_by_Recent_GI_Bleed

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000001
35,2020-11-25,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2020-11-25
PATIENT: HCC_Candidate_Excluded_by_Recent_GI_Bleed

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 203.98 ng/mL
- Total Bilirubin: 0.85 mg/dL
- Creatinine: 0.69 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7 with Esophageal Varices. Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000001
36,2020-12-24,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2020-12-24
PATIENT: HCC_Candidate_Excluded_by_Recent_GI_Bleed

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000001
37,2021-01-10,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2021-01-10
PATIENT: HCC_Candidate_Excluded_by_Recent_GI_Bleed

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 234.06 ng/mL
- Total Bilirubin: 0.75 mg/dL
- Creatinine: 0.76 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7 with Esophageal Varices. Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000001
38,2021-05-17,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2021-05-17
PATIENT: HCC_Candidate_Excluded_by_Recent_GI_Bleed

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000001
39,2021-05-21,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2021-05-21
PATIENT: HCC_Candidate_Excluded_by_Recent_GI_Bleed

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 281.88 ng/mL
- Total Bilirubin: 0.6 mg/dL
- Creatinine: 0.92 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7 with Esophageal Varices. Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000001
40,2021-07-13,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2021-07-13
PATIENT: HCC_Candidate_Excluded_by_Recent_GI_Bleed

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 253.05 ng/mL
- Total Bilirubin: 0.78 mg/dL
- Creatinine: 0.96 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7 with Esophageal Varices. Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000001
41,2021-11-21,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2021-11-21
PATIENT: HCC_Candidate_Excluded_by_Recent_GI_Bleed

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 193.27 ng/mL
- Total Bilirubin: 0.95 mg/dL
- Creatinine: 0.77 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7 with Esophageal Varices. Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000001
42,2021-12-13,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2021-12-13
PATIENT: HCC_Candidate_Excluded_by_Recent_GI_Bleed

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 191.34 ng/mL
- Total Bilirubin: 0.92 mg/dL
- Creatinine: 0.78 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7 with Esophageal Varices. Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000001
43,2022-03-04,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2022-03-04
PATIENT: HCC_Candidate_Excluded_by_Recent_GI_Bleed

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 179.33 ng/mL
- Total Bilirubin: 0.44 mg/dL
- Creatinine: 0.81 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7 with Esophageal Varices. Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000001
44,2022-05-25,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2022-05-25
PATIENT: HCC_Candidate_Excluded_by_Recent_GI_Bleed

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 115.23 ng/mL
- Total Bilirubin: 0.46 mg/dL
- Creatinine: 0.94 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7 with Esophageal Varices. Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000001
45,2022-08-23,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2022-08-23
PATIENT: HCC_Candidate_Excluded_by_Recent_GI_Bleed

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 117.92 ng/mL
- Total Bilirubin: 0.69 mg/dL
- Creatinine: 0.79 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7 with Esophageal Varices. Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000001
46,2022-10-25,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2022-10-25
PATIENT: HCC_Candidate_Excluded_by_Recent_GI_Bleed

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 95.86 ng/mL
- Total Bilirubin: 0.53 mg/dL
- Creatinine: 0.87 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7 with Esophageal Varices. Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000001
47,2022-11-18,Discharge Summary,"**Discharge Summary**

PATIENT: HCC_Candidate_Excluded_by_Recent_GI_Bleed
ADMISSION DATE: 2022-11-14
DISCHARGE DATE: 2022-11-18

ADMISSION DIAGNOSIS:
1. Upper GI Bleed secondary to Esophageal Varices

HOSPITAL COURSE:
The patient was admitted with hematemesis. EGD was performed which showed grade III esophageal varices with active bleeding. Successful band ligation was performed. Patient was stabilized with IV octreotide and blood transfusions. Remained hemodynamically stable post-procedure.

DISCHARGE DIAGNOSIS:
1. Resolved Upper GI Bleed
2. Esophageal Varices
3. Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7 with Esophageal Varices

PLAN:
1. Start Nadolol for primary prophylaxis.
2. Follow up in GI clinic in 2 weeks.
3. Continue HCC surveillance as outpatient.
",10000001
48,2022-12-28,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2022-12-28
PATIENT: HCC_Candidate_Excluded_by_Recent_GI_Bleed

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 83.49 ng/mL
- Total Bilirubin: 0.84 mg/dL
- Creatinine: 0.79 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7 with Esophageal Varices. Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000001
1,2018-01-10,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2018-01-10
PATIENT: HCC_Candidate_Excluded_by_Renal_Failure

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 173.75 ng/mL
- Total Bilirubin: 1.47 mg/dL
- Creatinine: 2.38 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7, Chronic Kidney Disease, Stage 4. Currently stable from an oncologic perspective.
Renal function is notably elevated, a concern for trial eligibility.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000002
2,2018-02-06,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2018-02-06
PATIENT: HCC_Candidate_Excluded_by_Renal_Failure

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 203.09 ng/mL
- Total Bilirubin: 1.23 mg/dL
- Creatinine: 2.45 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7, Chronic Kidney Disease, Stage 4. Currently stable from an oncologic perspective.
Renal function is notably elevated, a concern for trial eligibility.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000002
3,2018-03-18,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2018-03-18
PATIENT: HCC_Candidate_Excluded_by_Renal_Failure

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 240.35 ng/mL
- Total Bilirubin: 1.48 mg/dL
- Creatinine: 2.53 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7, Chronic Kidney Disease, Stage 4. Currently stable from an oncologic perspective.
Renal function is notably elevated, a concern for trial eligibility.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000002
4,2018-04-04,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2018-04-04
PATIENT: HCC_Candidate_Excluded_by_Renal_Failure

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 245.89 ng/mL
- Total Bilirubin: 1.32 mg/dL
- Creatinine: 2.43 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7, Chronic Kidney Disease, Stage 4. Currently stable from an oncologic perspective.
Renal function is notably elevated, a concern for trial eligibility.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000002
5,2018-05-09,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2018-05-09
PATIENT: HCC_Candidate_Excluded_by_Renal_Failure

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000002
6,2018-08-08,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2018-08-08
PATIENT: HCC_Candidate_Excluded_by_Renal_Failure

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 208.03 ng/mL
- Total Bilirubin: 1.24 mg/dL
- Creatinine: 2.38 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7, Chronic Kidney Disease, Stage 4. Currently stable from an oncologic perspective.
Renal function is notably elevated, a concern for trial eligibility.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000002
7,2018-10-14,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2018-10-14
PATIENT: HCC_Candidate_Excluded_by_Renal_Failure

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000002
8,2018-11-11,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2018-11-11
PATIENT: HCC_Candidate_Excluded_by_Renal_Failure

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 267.1 ng/mL
- Total Bilirubin: 0.91 mg/dL
- Creatinine: 2.12 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7, Chronic Kidney Disease, Stage 4. Currently stable from an oncologic perspective.
Renal function is notably elevated, a concern for trial eligibility.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000002
9,2018-12-18,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2018-12-18
PATIENT: HCC_Candidate_Excluded_by_Renal_Failure

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000002
10,2019-01-27,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2019-01-27
PATIENT: HCC_Candidate_Excluded_by_Renal_Failure

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000002
11,2019-02-12,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2019-02-12
PATIENT: HCC_Candidate_Excluded_by_Renal_Failure

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 223.25 ng/mL
- Total Bilirubin: 0.78 mg/dL
- Creatinine: 2.32 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7, Chronic Kidney Disease, Stage 4. Currently stable from an oncologic perspective.
Renal function is notably elevated, a concern for trial eligibility.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000002
12,2019-03-20,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2019-03-20
PATIENT: HCC_Candidate_Excluded_by_Renal_Failure

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000002
13,2019-04-16,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2019-04-16
PATIENT: HCC_Candidate_Excluded_by_Renal_Failure

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000002
14,2019-05-15,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2019-05-15
PATIENT: HCC_Candidate_Excluded_by_Renal_Failure

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 230.55 ng/mL
- Total Bilirubin: 0.58 mg/dL
- Creatinine: 2.75 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7, Chronic Kidney Disease, Stage 4. Currently stable from an oncologic perspective.
Renal function is notably elevated, a concern for trial eligibility.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000002
15,2019-06-21,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2019-06-21
PATIENT: HCC_Candidate_Excluded_by_Renal_Failure

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 213.54 ng/mL
- Total Bilirubin: 0.76 mg/dL
- Creatinine: 2.86 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7, Chronic Kidney Disease, Stage 4. Currently stable from an oncologic perspective.
Renal function is notably elevated, a concern for trial eligibility.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000002
16,2019-06-21,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2019-06-21
PATIENT: HCC_Candidate_Excluded_by_Renal_Failure

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000002
17,2019-07-07,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2019-07-07
PATIENT: HCC_Candidate_Excluded_by_Renal_Failure

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 169.99 ng/mL
- Total Bilirubin: 0.8 mg/dL
- Creatinine: 3.07 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7, Chronic Kidney Disease, Stage 4. Currently stable from an oncologic perspective.
Renal function is notably elevated, a concern for trial eligibility.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000002
18,2019-09-18,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2019-09-18
PATIENT: HCC_Candidate_Excluded_by_Renal_Failure

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 186.04 ng/mL
- Total Bilirubin: 1.12 mg/dL
- Creatinine: 3.11 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7, Chronic Kidney Disease, Stage 4. Currently stable from an oncologic perspective.
Renal function is notably elevated, a concern for trial eligibility.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000002
19,2019-10-02,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2019-10-02
PATIENT: HCC_Candidate_Excluded_by_Renal_Failure

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000002
20,2019-11-17,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2019-11-17
PATIENT: HCC_Candidate_Excluded_by_Renal_Failure

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000002
21,2020-02-20,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2020-02-20
PATIENT: HCC_Candidate_Excluded_by_Renal_Failure

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 181.93 ng/mL
- Total Bilirubin: 1.13 mg/dL
- Creatinine: 3.22 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7, Chronic Kidney Disease, Stage 4. Currently stable from an oncologic perspective.
Renal function is notably elevated, a concern for trial eligibility.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000002
22,2020-03-17,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2020-03-17
PATIENT: HCC_Candidate_Excluded_by_Renal_Failure

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 127.0 ng/mL
- Total Bilirubin: 1.12 mg/dL
- Creatinine: 3.18 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7, Chronic Kidney Disease, Stage 4. Currently stable from an oncologic perspective.
Renal function is notably elevated, a concern for trial eligibility.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000002
23,2020-04-23,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2020-04-23
PATIENT: HCC_Candidate_Excluded_by_Renal_Failure

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 159.89 ng/mL
- Total Bilirubin: 1.15 mg/dL
- Creatinine: 3.34 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7, Chronic Kidney Disease, Stage 4. Currently stable from an oncologic perspective.
Renal function is notably elevated, a concern for trial eligibility.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000002
24,2020-05-11,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2020-05-11
PATIENT: HCC_Candidate_Excluded_by_Renal_Failure

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 194.31 ng/mL
- Total Bilirubin: 1.11 mg/dL
- Creatinine: 3.41 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7, Chronic Kidney Disease, Stage 4. Currently stable from an oncologic perspective.
Renal function is notably elevated, a concern for trial eligibility.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000002
25,2020-06-12,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2020-06-12
PATIENT: HCC_Candidate_Excluded_by_Renal_Failure

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000002
26,2020-07-03,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2020-07-03
PATIENT: HCC_Candidate_Excluded_by_Renal_Failure

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 177.46 ng/mL
- Total Bilirubin: 1.16 mg/dL
- Creatinine: 3.39 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7, Chronic Kidney Disease, Stage 4. Currently stable from an oncologic perspective.
Renal function is notably elevated, a concern for trial eligibility.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000002
27,2020-07-16,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2020-07-16
PATIENT: HCC_Candidate_Excluded_by_Renal_Failure

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000002
28,2020-09-12,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2020-09-12
PATIENT: HCC_Candidate_Excluded_by_Renal_Failure

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000002
29,2020-12-02,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2020-12-02
PATIENT: HCC_Candidate_Excluded_by_Renal_Failure

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 200.1 ng/mL
- Total Bilirubin: 1.65 mg/dL
- Creatinine: 2.73 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7, Chronic Kidney Disease, Stage 4. Currently stable from an oncologic perspective.
Renal function is notably elevated, a concern for trial eligibility.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000002
30,2021-01-12,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2021-01-12
PATIENT: HCC_Candidate_Excluded_by_Renal_Failure

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000002
31,2021-02-03,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2021-02-03
PATIENT: HCC_Candidate_Excluded_by_Renal_Failure

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 260.44 ng/mL
- Total Bilirubin: 1.86 mg/dL
- Creatinine: 2.4 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7, Chronic Kidney Disease, Stage 4. Currently stable from an oncologic perspective.
Renal function is notably elevated, a concern for trial eligibility.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000002
32,2021-05-06,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2021-05-06
PATIENT: HCC_Candidate_Excluded_by_Renal_Failure

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 316.49 ng/mL
- Total Bilirubin: 2.0 mg/dL
- Creatinine: 2.2 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7, Chronic Kidney Disease, Stage 4. Currently stable from an oncologic perspective.
Renal function is notably elevated, a concern for trial eligibility.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000002
33,2021-05-19,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2021-05-19
PATIENT: HCC_Candidate_Excluded_by_Renal_Failure

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000002
34,2021-06-02,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2021-06-02
PATIENT: HCC_Candidate_Excluded_by_Renal_Failure

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000002
35,2021-08-03,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2021-08-03
PATIENT: HCC_Candidate_Excluded_by_Renal_Failure

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000002
36,2021-09-18,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2021-09-18
PATIENT: HCC_Candidate_Excluded_by_Renal_Failure

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 471.13 ng/mL
- Total Bilirubin: 2.03 mg/dL
- Creatinine: 2.59 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7, Chronic Kidney Disease, Stage 4. Currently stable from an oncologic perspective.
Renal function is notably elevated, a concern for trial eligibility.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000002
37,2021-10-07,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2021-10-07
PATIENT: HCC_Candidate_Excluded_by_Renal_Failure

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 487.4 ng/mL
- Total Bilirubin: 2.15 mg/dL
- Creatinine: 2.38 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7, Chronic Kidney Disease, Stage 4. Currently stable from an oncologic perspective.
Renal function is notably elevated, a concern for trial eligibility.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000002
38,2021-11-10,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2021-11-10
PATIENT: HCC_Candidate_Excluded_by_Renal_Failure

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000002
39,2021-12-27,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2021-12-27
PATIENT: HCC_Candidate_Excluded_by_Renal_Failure

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 526.86 ng/mL
- Total Bilirubin: 1.72 mg/dL
- Creatinine: 3.0 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7, Chronic Kidney Disease, Stage 4. Currently stable from an oncologic perspective.
Renal function is notably elevated, a concern for trial eligibility.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000002
40,2022-01-05,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2022-01-05
PATIENT: HCC_Candidate_Excluded_by_Renal_Failure

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000002
41,2022-02-28,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2022-02-28
PATIENT: HCC_Candidate_Excluded_by_Renal_Failure

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 500.19 ng/mL
- Total Bilirubin: 1.7 mg/dL
- Creatinine: 3.14 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7, Chronic Kidney Disease, Stage 4. Currently stable from an oncologic perspective.
Renal function is notably elevated, a concern for trial eligibility.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000002
42,2022-03-21,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2022-03-21
PATIENT: HCC_Candidate_Excluded_by_Renal_Failure

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000002
43,2022-03-26,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2022-03-26
PATIENT: HCC_Candidate_Excluded_by_Renal_Failure

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 467.18 ng/mL
- Total Bilirubin: 1.6 mg/dL
- Creatinine: 3.34 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7, Chronic Kidney Disease, Stage 4. Currently stable from an oncologic perspective.
Renal function is notably elevated, a concern for trial eligibility.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000002
44,2022-05-03,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2022-05-03
PATIENT: HCC_Candidate_Excluded_by_Renal_Failure

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 462.9 ng/mL
- Total Bilirubin: 1.34 mg/dL
- Creatinine: 3.34 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh B7, Chronic Kidney Disease, Stage 4. Currently stable from an oncologic perspective.
Renal function is notably elevated, a concern for trial eligibility.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000002
45,2022-05-10,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2022-05-10
PATIENT: HCC_Candidate_Excluded_by_Renal_Failure

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000002
46,2022-06-02,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2022-06-02
PATIENT: HCC_Candidate_Excluded_by_Renal_Failure

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000002
47,2022-07-16,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2022-07-16
PATIENT: HCC_Candidate_Excluded_by_Renal_Failure

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000002
48,2022-08-22,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2022-08-22
PATIENT: HCC_Candidate_Excluded_by_Renal_Failure

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000002
49,2022-12-14,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2022-12-14
PATIENT: HCC_Candidate_Excluded_by_Renal_Failure

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000002
1,2018-01-02,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2018-01-02
PATIENT: HCC_Candidate_Excluded_by_Hypoxia

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 90.64 ng/mL
- Total Bilirubin: 0.84 mg/dL
- Creatinine: 1.02 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh A, Severe COPD requiring intermittent home oxygen. Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000003
2,2018-02-15,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2018-02-15
PATIENT: HCC_Candidate_Excluded_by_Hypoxia

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 116.27 ng/mL
- Total Bilirubin: 0.87 mg/dL
- Creatinine: 1.17 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh A, Severe COPD requiring intermittent home oxygen. Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000003
3,2018-03-08,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2018-03-08
PATIENT: HCC_Candidate_Excluded_by_Hypoxia

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000003
4,2018-04-16,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2018-04-16
PATIENT: HCC_Candidate_Excluded_by_Hypoxia

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 66.74 ng/mL
- Total Bilirubin: 0.73 mg/dL
- Creatinine: 1.23 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh A, Severe COPD requiring intermittent home oxygen. Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000003
5,2018-05-15,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2018-05-15
PATIENT: HCC_Candidate_Excluded_by_Hypoxia

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 69.0 ng/mL
- Total Bilirubin: 0.66 mg/dL
- Creatinine: 1.33 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh A, Severe COPD requiring intermittent home oxygen. Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000003
6,2018-06-08,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2018-06-08
PATIENT: HCC_Candidate_Excluded_by_Hypoxia

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000003
7,2018-06-13,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2018-06-13
PATIENT: HCC_Candidate_Excluded_by_Hypoxia

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 56.4 ng/mL
- Total Bilirubin: 0.63 mg/dL
- Creatinine: 1.42 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh A, Severe COPD requiring intermittent home oxygen. Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000003
8,2018-08-17,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2018-08-17
PATIENT: HCC_Candidate_Excluded_by_Hypoxia

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000003
9,2018-09-06,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2018-09-06
PATIENT: HCC_Candidate_Excluded_by_Hypoxia

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000003
10,2018-10-24,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2018-10-24
PATIENT: HCC_Candidate_Excluded_by_Hypoxia

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 6.15 ng/mL
- Total Bilirubin: 0.75 mg/dL
- Creatinine: 1.54 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh A, Severe COPD requiring intermittent home oxygen. Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000003
11,2018-11-04,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2018-11-04
PATIENT: HCC_Candidate_Excluded_by_Hypoxia

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 46.17 ng/mL
- Total Bilirubin: 0.7 mg/dL
- Creatinine: 1.6 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh A, Severe COPD requiring intermittent home oxygen. Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000003
12,2018-11-08,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2018-11-08
PATIENT: HCC_Candidate_Excluded_by_Hypoxia

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000003
13,2018-12-03,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2018-12-03
PATIENT: HCC_Candidate_Excluded_by_Hypoxia

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000003
14,2019-02-05,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2019-02-05
PATIENT: HCC_Candidate_Excluded_by_Hypoxia

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000003
15,2019-06-10,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2019-06-10
PATIENT: HCC_Candidate_Excluded_by_Hypoxia

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 176.04 ng/mL
- Total Bilirubin: 0.89 mg/dL
- Creatinine: 1.76 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh A, Severe COPD requiring intermittent home oxygen. Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000003
16,2019-08-06,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2019-08-06
PATIENT: HCC_Candidate_Excluded_by_Hypoxia

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 164.09 ng/mL
- Total Bilirubin: 0.98 mg/dL
- Creatinine: 1.77 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh A, Severe COPD requiring intermittent home oxygen. Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000003
17,2019-10-05,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2019-10-05
PATIENT: HCC_Candidate_Excluded_by_Hypoxia

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 173.43 ng/mL
- Total Bilirubin: 1.13 mg/dL
- Creatinine: 1.82 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh A, Severe COPD requiring intermittent home oxygen. Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000003
18,2020-01-09,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2020-01-09
PATIENT: HCC_Candidate_Excluded_by_Hypoxia

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 130.91 ng/mL
- Total Bilirubin: 1.3 mg/dL
- Creatinine: 1.68 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh A, Severe COPD requiring intermittent home oxygen. Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000003
19,2020-02-14,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2020-02-14
PATIENT: HCC_Candidate_Excluded_by_Hypoxia

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 140.86 ng/mL
- Total Bilirubin: 1.14 mg/dL
- Creatinine: 1.72 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh A, Severe COPD requiring intermittent home oxygen. Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000003
20,2020-04-26,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2020-04-26
PATIENT: HCC_Candidate_Excluded_by_Hypoxia

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 138.02 ng/mL
- Total Bilirubin: 1.41 mg/dL
- Creatinine: 1.85 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh A, Severe COPD requiring intermittent home oxygen. Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000003
21,2020-05-08,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2020-05-08
PATIENT: HCC_Candidate_Excluded_by_Hypoxia

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 117.4 ng/mL
- Total Bilirubin: 1.52 mg/dL
- Creatinine: 1.81 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh A, Severe COPD requiring intermittent home oxygen. Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000003
22,2020-06-22,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2020-06-22
PATIENT: HCC_Candidate_Excluded_by_Hypoxia

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 96.03 ng/mL
- Total Bilirubin: 1.64 mg/dL
- Creatinine: 1.94 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh A, Severe COPD requiring intermittent home oxygen. Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000003
23,2020-07-15,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2020-07-15
PATIENT: HCC_Candidate_Excluded_by_Hypoxia

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 108.96 ng/mL
- Total Bilirubin: 1.56 mg/dL
- Creatinine: 1.88 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh A, Severe COPD requiring intermittent home oxygen. Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000003
24,2020-08-21,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2020-08-21
PATIENT: HCC_Candidate_Excluded_by_Hypoxia

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 105.49 ng/mL
- Total Bilirubin: 1.63 mg/dL
- Creatinine: 1.78 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh A, Severe COPD requiring intermittent home oxygen. Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000003
25,2020-09-01,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2020-09-01
PATIENT: HCC_Candidate_Excluded_by_Hypoxia

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 111.22 ng/mL
- Total Bilirubin: 1.61 mg/dL
- Creatinine: 1.74 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh A, Severe COPD requiring intermittent home oxygen. Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000003
26,2020-10-12,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2020-10-12
PATIENT: HCC_Candidate_Excluded_by_Hypoxia

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 112.03 ng/mL
- Total Bilirubin: 1.72 mg/dL
- Creatinine: 1.85 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh A, Severe COPD requiring intermittent home oxygen. Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000003
27,2020-11-15,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2020-11-15
PATIENT: HCC_Candidate_Excluded_by_Hypoxia

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000003
28,2021-02-19,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2021-02-19
PATIENT: HCC_Candidate_Excluded_by_Hypoxia

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 137.86 ng/mL
- Total Bilirubin: 1.66 mg/dL
- Creatinine: 1.53 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh A, Severe COPD requiring intermittent home oxygen. Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000003
29,2021-03-23,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2021-03-23
PATIENT: HCC_Candidate_Excluded_by_Hypoxia

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 131.14 ng/mL
- Total Bilirubin: 1.63 mg/dL
- Creatinine: 1.47 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh A, Severe COPD requiring intermittent home oxygen. Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000003
30,2021-04-26,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2021-04-26
PATIENT: HCC_Candidate_Excluded_by_Hypoxia

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000003
31,2021-06-22,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2021-06-22
PATIENT: HCC_Candidate_Excluded_by_Hypoxia

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 81.16 ng/mL
- Total Bilirubin: 1.95 mg/dL
- Creatinine: 1.57 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh A, Severe COPD requiring intermittent home oxygen. Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000003
32,2021-08-27,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2021-08-27
PATIENT: HCC_Candidate_Excluded_by_Hypoxia

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000003
33,2021-08-28,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2021-08-28
PATIENT: HCC_Candidate_Excluded_by_Hypoxia

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 86.87 ng/mL
- Total Bilirubin: 2.17 mg/dL
- Creatinine: 1.58 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh A, Severe COPD requiring intermittent home oxygen. Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000003
34,2022-01-22,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2022-01-22
PATIENT: HCC_Candidate_Excluded_by_Hypoxia

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 120.32 ng/mL
- Total Bilirubin: 2.44 mg/dL
- Creatinine: 1.89 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh A, Severe COPD requiring intermittent home oxygen. Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000003
35,2022-03-23,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2022-03-23
PATIENT: HCC_Candidate_Excluded_by_Hypoxia

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 139.39 ng/mL
- Total Bilirubin: 2.54 mg/dL
- Creatinine: 2.05 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh A, Severe COPD requiring intermittent home oxygen. Currently stable from an oncologic perspective.
Renal function is notably elevated, a concern for trial eligibility.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000003
36,2022-04-27,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2022-04-27
PATIENT: HCC_Candidate_Excluded_by_Hypoxia

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000003
37,2022-05-04,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2022-05-04
PATIENT: HCC_Candidate_Excluded_by_Hypoxia

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 141.38 ng/mL
- Total Bilirubin: 2.63 mg/dL
- Creatinine: 1.91 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh A, Severe COPD requiring intermittent home oxygen. Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000003
38,2022-05-27,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2022-05-27
PATIENT: HCC_Candidate_Excluded_by_Hypoxia

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000003
39,2022-06-10,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2022-06-10
PATIENT: HCC_Candidate_Excluded_by_Hypoxia

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 132.46 ng/mL
- Total Bilirubin: 2.7 mg/dL
- Creatinine: 1.78 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh A, Severe COPD requiring intermittent home oxygen. Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000003
40,2022-09-28,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2022-09-28
PATIENT: HCC_Candidate_Excluded_by_Hypoxia

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 152.3 ng/mL
- Total Bilirubin: 2.8 mg/dL
- Creatinine: 1.48 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh A, Severe COPD requiring intermittent home oxygen. Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000003
41,2022-10-07,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2022-10-07
PATIENT: HCC_Candidate_Excluded_by_Hypoxia

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000003
42,2022-10-23,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2022-10-23
PATIENT: HCC_Candidate_Excluded_by_Hypoxia

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 140.41 ng/mL
- Total Bilirubin: 3.05 mg/dL
- Creatinine: 1.48 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh A, Severe COPD requiring intermittent home oxygen. Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000003
43,2022-11-21,Radiology Report,"**Radiology Report: MRI Abdomen w/wo Contrast**

EXAM DATE: 2022-11-21
PATIENT: HCC_Candidate_Excluded_by_Hypoxia

REASON FOR EXAM: Surveillance of hepatocellular carcinoma.

FINDINGS:
The liver demonstrates a cirrhotic morphology. There is a [not applicable for this patient] cm arterially enhancing lesion in segment 6 with washout on delayed phases, consistent with known HCC. No evidence of major vascular invasion. No new suspicious lesions are identified.

IMPRESSION:
1. Stable appearance of the known [not applicable for this patient] cm HCC in segment 6.
2. No evidence of new disease or metastatic spread.
",10000003
44,2022-12-25,Oncology Clinic Note,"**Oncology Clinic Progress Note**

DATE: 2022-12-25
PATIENT: HCC_Candidate_Excluded_by_Hypoxia

SUBJECTIVE:
Patient seen in clinic for routine follow-up of HCC. Reports stable energy levels. Denies new abdominal pain, fever, or chills.

OBJECTIVE:
Vitals stable. Exam unremarkable.
Today's Labs:
- AFP: 164.99 ng/mL
- Total Bilirubin: 3.34 mg/dL
- Creatinine: 1.48 mg/dL

ASSESSMENT:
Patient with Hepatocellular Carcinoma (HCC), BCLC Stage B, Liver Cirrhosis, Child-Pugh A, Severe COPD requiring intermittent home oxygen. Currently stable from an oncologic perspective.
Renal function is stable.

PLAN:
1. Continue current management.
2. Discussed eligibility for TATE vs TACE clinical trial.
3. Follow-up in 2 months with repeat labs.
4. MRI abdomen scheduled next month to monitor tumor status.
",10000003
